Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
P/E ratio for Madrigal Pharmaceuticals, Inc. (MDGL)
P/E ratio as of 2023: -11.57
According to Madrigal Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -11.57. At the end of 2022 the company had a P/E ratio of -16.62.
P/E ratio history for Madrigal Pharmaceuticals, Inc. from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -11.57 |
| 2022 | -16.62 |
| 2021 | -5.81 |
| 2020 | -8.70 |
| 2019 | -19.26 |
| 2018 | -50.83 |
| 2017 | -36.08 |
| 2016 | -2.94 |
| 2015 | -0.03 |
| 2014 | -3.03 |
| 2013 | -4.12 |
| 2012 | -8.53 |
| 2011 | -4.65 |
| 2010 | -6.59 |
| 2009 | 2.17 |
| 2008 | -2.23 |
| 2007 | -3.43 |
| 2006 | -3.53 |
| 2005 | -2.94 |
| 2004 | -3.70 |
| 2003 | -7.13 |
| 2002 | -3.03 |
| 2001 | -69.92 |